ConductScience.org, home

Trial · NCT01489176

Regadenoson Real Time Perfusion Imaging Trial-Optison

NCT01489176, Phase 3, Completed, University of Nebraska; results first posted 2022-12-30

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Regadenoson Real Time Perfusion Imaging Trial-Optison. Trials, record NCT01489176. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01489176

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Regadenoson Real Time Perfusion Imaging Trial-Optison
NCT number
NCT01489176
Status
Completed
Phases
Phase 3
Enrollment
50 participants, actual
Lead sponsor
University of Nebraska
Conditions
Coronary Artery Disease, Myocardial Perfusion Abnormalities
Interventions
Regadenoson; Optison
First posted
2011-12-09
Last updated
2024-10-08
Results first posted
2022-12-30

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryNumber of Participants With Coronary Stenosis1 yearMeasurements will be analyzed to identify a coronary stenosis \>50% in diameter by quantitative cardiac angiography.

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYNumber of Participants With Coronary Stenosis1 yearParticipantsCOUNT_OF_PARTICIPANTS

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Number of Participants With Coronary StenosisRegadenoson; Optison50Participants

Participant flow3

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDRegadenoson; Optison50
Overall StudyCOMPLETEDRegadenoson; Optison50
Overall StudyNOT COMPLETEDRegadenoson; Optison0

Adverse events3

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherChest PainCardiac disordersRegadenoson; Optison7507
otherShortness of BreathRespiratory, thoracic and mediastinal disordersRegadenoson; Optison265026
otherHeadachesGeneral disordersRegadenoson; Optison185018

Adverse event totals3

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityRegadenoson; Optison050
Total, other adverse eventsRegadenoson; Optison5050
Total, serious adverse eventsRegadenoson; Optison050

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01489176

GET https://conductscience.org/api/trials/v1/NCT01489176/registered